PhRMA Awards Celebrate Breakthroughs – And Get Warning On Prices
Executive Summary
Merck's Keytruda highlights promise of FDA designation, but Tom Brokaw notes perils of industry's pricing strategy.
You may also be interested in...
Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing
FDA extends the PDUFA date for enzyme replacement therapy by three months so agency can review chemistry, manufacturing and controls information; another drug, Strensiq, is also pending at FDA without any action.
FDA Soft Sells GMP Quality Overhaul For Generics; Don’t Be ‘Anxious,’ Woodcock Says
‘In some ways our practices have played into the problems we’ve been having,’ CDER director tells GPhA annual meeting as she outlines her plan to ‘radically change’ manufacturing oversight.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.